Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences
September 28 2017 - 6:00AM
Vical Incorporated (Nasdaq:VICL) announced today that the company
will present a poster on its antifungal VL-2397 development program
at the Infectious Diseases Society of America (IDSA) IDWeek 2017,
being held in San Diego, CA, from October 4 to 8, 2017. The poster
session will be on Friday October 6th from 12:30 to 2:00 pm.
The title of the presentation is
“Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to
Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with
Invasive Aspergillosis”. The analysis concluded that a 600
milligram dose of VL-2397 administered once daily will provide
adequate target attainment. The analysis will serve as the basis
for using this dosing regimen in Vical’s upcoming Phase 2 trial in
patients with invasive aspergillosis.
Vical also announced today that the company will
provide an update on VL-2397 at the 8th Trends in Medical Mycology
(TIMM) Conference, being held in Belgrade, Serbia, from October 6
to 9, 2017. The presentation will be on October 8th at 2:15 pm
CET.
Vical plans to conduct a Phase 2 efficacy study
to evaluate VL-2397 for the treatment of invasive aspergillosis and
is working with clinical experts and the FDA towards this
objective. The FDA has granted Vical Qualified Infectious Disease
Product (QIDP), Orphan Drug and Fast Track designations to VL-2397
for the treatment of invasive aspergillosis. Under the QIDP
designation Vical has been interacting with the FDA on the design
of the Phase 2 trial and in exploring an expedited development
pathway for VL‑2397.
About VL-2397VL-2397 is Vical’s
novel antifungal compound that was licensed from Astellas Pharma in
2015. VL-2397 was isolated from a leaf litter fungus collected in a
Malaysian national park and represents the first agent in a
potentially new class of antifungal drugs.
About VicalVical develops
biopharmaceutical products for the prevention and treatment of
chronic or life-threatening infectious diseases, based on its
patented DNA delivery technologies and other therapeutic
approaches. Additional information on Vical is available at
www.vical.com.
Forward-Looking StatementsThis
press release contains forward-looking statements subject to risks
and uncertainties that could cause actual results to differ
materially from those projected. Forward-looking statements include
anticipated developments in clinical programs, including the plans,
timing of initiation, and enrollment for clinical trials. Risks and
uncertainties include whether Vical or others will continue
development of VL-2397; whether Vical will be able to obtain
regulatory allowances or guidance necessary to proceed with
proposed clinical trials or implement anticipated clinical trial
designs; whether on-going or planned clinical trials will be
initiated or completed on the timelines Vical currently expects,
whether any product candidates will be shown to be safe and
efficacious in clinical trials; whether Vical will have access to
sufficient capital to fund its planned development activities;
whether Vical will seek or gain approval to market any product
candidates; and additional risks set forth in the Company's filings
with the Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
Contact:Andrew Hopkins(858)
646-1127Website: www.vical.com
Vical (NASDAQ:VICL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vical (NASDAQ:VICL)
Historical Stock Chart
From Apr 2023 to Apr 2024